Laurus opens commercial-scale peptide plant, moves into resin manufacturing
Laurus Labs has inaugurated its first commercial-scale peptide manufacturing facility in Vizag, India, with more than 16,000 litres of solid-phase peptide synthesis (SPPS) capacity, according to its October 29 financial results announcement.
The company said further peptide capacity expansion is underway but did not disclose additional volumes, utilization rates or commercial shipment figures. The reported 16,000 litres represents synthesis equipment capacity, not annual peptide API production.
Alongside the manufacturing expansion, Laurus has agreed to invest ₹32.50 crore (approximately $3.7 million) for a proposed 52% stake in Hyderabad-based SI&C Resins, a supplier of materials used in peptide synthesis and purification. The investment remains subject to closing conditions, including the transfer of SI&C's existing partnership business into the company.
SI&C plans to establish a large-scale manufacturing facility for solid-phase peptide synthesis supports and chromatography gels. The materials serve two critical stages of peptide production: resins support peptide-chain assembly during synthesis, while chromatography gels enable downstream separation and purification.
Laurus may subsequently invest up to a further ₹30 crore (approximately $3.4 million) to support the business as funding is required. Neither the proposed resin plant's capacity nor its startup timetable has been disclosed.
The two developments position Laurus to expand peptide API manufacturing while securing greater involvement in the specialized materials required to produce and purify peptides.